MANENYSEPharmaceutical PreparationsFiscal year ends December 31
Veradermics, Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$122.28+13.46 (+12.37%)
Close on Oct 19, 2026
- Market cap
- $4.94B
- P/E (TTM)
- –
- Dividend yield
- –
SEC filings
12 of Veradermics's most recent filings on SEC EDGAR
| Document | Form | Period | Filed | Source |
|---|---|---|---|---|
| Current report | 8-K | Oct 19, 2026 | Oct 19, 2026 | SEC EDGAR |
| Quarterly report | 10-Q | Jun 30, 2026 | Aug 11, 2026 | SEC EDGAR |
| Current report | 8-K | Aug 11, 2026 | Aug 11, 2026 | SEC EDGAR |
| Current report | 8-K | Jul 15, 2026 | Jul 15, 2026 | SEC EDGAR |
| Quarterly report | 10-Q | Mar 31, 2026 | May 12, 2026 | SEC EDGAR |
| Current report | 8-K | May 12, 2026 | May 12, 2026 | SEC EDGAR |
| Current report | 8-K | May 1, 2026 | May 1, 2026 | SEC EDGAR |
| Current report | 8-K | Apr 27, 2026 | Apr 27, 2026 | SEC EDGAR |
| Current report | 8-K | Apr 27, 2026 | Apr 27, 2026 | SEC EDGAR |
| Annual report | 10-K | Dec 31, 2025 | Mar 30, 2026 | SEC EDGAR |
| Current report | 8-K | Mar 30, 2026 | Mar 30, 2026 | SEC EDGAR |
| Current report | 8-K | Feb 5, 2026 | Feb 5, 2026 | SEC EDGAR |